BR0318242A - derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação - Google Patents

derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação

Info

Publication number
BR0318242A
BR0318242A BRPI0318242-8A BR0318242A BR0318242A BR 0318242 A BR0318242 A BR 0318242A BR 0318242 A BR0318242 A BR 0318242A BR 0318242 A BR0318242 A BR 0318242A
Authority
BR
Brazil
Prior art keywords
preparation
receptor antagonists
muscarinic receptor
derivatives
compounds
Prior art date
Application number
BRPI0318242-8A
Other languages
English (en)
Inventor
Anita Mehta
Arundutt Viswanatham Silamkoti
Jang Bahadur Gupta
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0318242A publication Critical patent/BR0318242A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE AZABICICLO HEXANO SUBSTITUìDOS COMO ANTAGONISTAS DE RECEPTORES MUSCARìNICOS E PROCESSO PARA SUA PREPARAçãO". A presente invenção refere-se a derivados de azabiciclo hexanos substituídos de Fórmula I. Os compostos da presente invenção podem atuar como antagonistas de receptores muscarínicos e podem ser utilizados no tratamento de várias doenças dos sistemas respiratório, urinário e gastrointestinal que são mediadas por receptores muscarínicos. A invenção também se refere a um processo para a preparação dos compostos acima referidos, a composições farmacêuticas contendo tais compostos e ao uso da composição farmacêutica no tratamento de doenças mediadas por receptores muscarínicos.
BRPI0318242-8A 2003-04-10 2003-04-10 derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação BR0318242A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/001333 WO2004089363A1 (en) 2003-04-10 2003-04-10 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
BR0318242A true BR0318242A (pt) 2006-04-04

Family

ID=33156168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318242-8A BR0318242A (pt) 2003-04-10 2003-04-10 derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação

Country Status (11)

Country Link
US (1) US7592359B2 (pt)
EP (1) EP1615634B1 (pt)
JP (1) JP2006514978A (pt)
CN (1) CN100406009C (pt)
AT (1) ATE362364T1 (pt)
AU (1) AU2003214535B2 (pt)
BR (1) BR0318242A (pt)
CA (1) CA2521788A1 (pt)
DE (1) DE60313898T2 (pt)
EA (1) EA009059B1 (pt)
WO (1) WO2004089363A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2007007281A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1934184A1 (en) 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
US20100222393A1 (en) 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
US20090137623A1 (en) 2005-12-30 2009-05-28 Naresh Kumar Muscarinic receptor antagonists
WO2008029349A2 (en) * 2006-09-04 2008-03-13 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2022034146A1 (en) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (pt) 1960-07-26
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
IE66202B1 (en) 1989-08-16 1995-12-13 Pfizer Azabicyclo quinolone carboxylic acids
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5281601A (en) * 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
KR19990008109A (ko) 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AU2793197A (en) 1996-05-31 1998-01-05 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
RU2238936C2 (ru) * 1996-11-11 2004-10-27 Кристиан Р. НОЕ Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
US7232835B2 (en) * 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists

Also Published As

Publication number Publication date
EA200501594A1 (ru) 2006-08-25
CA2521788A1 (en) 2004-10-21
US7592359B2 (en) 2009-09-22
DE60313898T2 (de) 2008-01-17
EA009059B1 (ru) 2007-10-26
EP1615634B1 (en) 2007-05-16
DE60313898D1 (de) 2007-06-28
CN100406009C (zh) 2008-07-30
AU2003214535A8 (en) 2004-11-01
EP1615634A1 (en) 2006-01-18
JP2006514978A (ja) 2006-05-18
US20070287732A1 (en) 2007-12-13
ATE362364T1 (de) 2007-06-15
AU2003214535B2 (en) 2009-09-03
CN1794984A (zh) 2006-06-28
AU2003214535A1 (en) 2004-11-01
WO2004089363A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
TW200510429A (en) Heterocyclic MCHR1 antagonists
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
MY137535A (en) New pyrrolidinium derivatives
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
DE60309829D1 (de) Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
EP2202222A3 (en) Indene derivatives, their preparation and use as medicaments
CO5180642A1 (es) Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BRPI0417323A (pt) indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
ATE386725T1 (de) Heterocyclylverbindungen
BRPI0809981A2 (pt) Compostos, processo de fabricação destes, composição farmacêutica que os contém, método de tratamento e/ou prevenção de doenças que são associadas a modulação de receptores de sst subtipo 5 e uso dos compostos.
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
BRPI0409308A (pt) derivados azabiciclo como antagonistas de receptores muscarìnicos, composição farmacêutica e processo para sua preparação
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
MX2009005507A (es) Derivados de espiro-piperidina.
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
BRPI0409436A (pt) compostos de 4-fenil-piperidina e a sua utilização como moduladores de receptores de opióides

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.